Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).
暂无分享,去创建一个
R. Kaji | S. Kozaki | Motohide Takahashi | S. Ishida | Yasushi Torii | Tetsuhiro Harakawa | A. Ginnaga | Yoshitaka Goto | S. Nakahira
[1] R. Kaji,et al. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins. , 2010, Toxicon : official journal of the International Society on Toxinology.
[2] V. Tugnoli,et al. Botulinum Toxin for Pain , 2008, Drugs in R&D.
[3] D. Sesardic,et al. A review of WHO International Standards for botulinum antitoxins. , 2006, Biologicals : journal of the International Association of Biological Standardization.
[4] W. Jost,et al. Botulinum toxin: clinical use. , 2006, Parkinsonism & related disorders.
[5] J. Jankovic,et al. Botulinum toxin in clinical practice , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[6] Dorothea Sesardic,et al. Detection of antibodies against botulinum toxins , 2004, Movement disorders : official journal of the Movement Disorder Society.
[7] D. Dressler. Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy , 2004, Movement disorders : official journal of the Movement Disorder Society.
[8] Roberto Eleopra,et al. Different types of botulinum toxin in humans , 2004, Movement disorders : official journal of the Movement Disorder Society.
[9] S. Kozaki,et al. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. , 2002, Vaccine.
[10] V. Tugnoli,et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans , 1998, Neuroscience Letters.
[11] Leonard A. Smith,et al. Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate , 1998, Infection and Immunity.
[12] R. Benecke,et al. The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A , 1997 .
[13] M. Goodnough,et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials , 1996, Neurology.
[14] M. Brin,et al. Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm , 1995, Neurology.
[15] J. Snyder,et al. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. , 1984, The Journal of infectious diseases.
[16] G. Sakaguchi,et al. PURIFICATION AND ORAL TOXICITIES OF CLOSTRIDIUM BOTULINUM PROGENITOR TOXINS , 1981 .